Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapies, with a current focus on pulmonary arterial hypertension (PAH) through its IKT-001 program. The company has no commercial product revenue yet and is still in the development and regulatory approval phase, relying on external manufacturers, CROs, and financing to advance its pipeline.

21.70

21.70

— Inhibikase Therapeutics, Inc.
%
Clinical-stage drug candidates70% Development programs for IKT-001 and other product candidates intended for future regulatory approval.
Prodrug technology platform15% Underlying chemistry and formulation work used to create and optimize therapeutic candidates.
Biomarker and translational research10% Research tools and studies used to show target engagement and disease impact in trials.
Future commercialization rights5% Rights to market approved products if clinical and regulatory milestones are achieved.

The company does not currently sell commercial products, so its near-term 'customers' are primarily clinical...

  • Clinical development partnersprimary

    CROs, trial sites, and consultants that execute preclinical and clinical studies needed to advance IKT-001.

  • Manufacturing partnersprimary

    Third-party CMOs, including China-based suppliers, that produce clinical and future commercial supply.

  • Regulatory authoritiesprimary

    U.S. and other regulators that determine whether product candidates can progress to approval and commercialization.

  • Future specialty prescribersemerging

    Pulmonologists and specialty centers that would prescribe an approved PAH therapy.

  • Patients with PAHemerging

    Patients with pulmonary arterial hypertension who would use the therapy if it is approved and reimbursed.

Inhibikase is headquartered in the United States, but its operating footprint is global because key manufacturing is...

  • •United States is the core base for R&D, financing, and regulatory activity
  • •China is a critical manufacturing location for current and future product candidates
  • •Global sourcing increases exposure to trade, tariff, and policy disruptions
  • •Clinical development is centered on outsourced trial execution rather than owned sites
  • •No country-level revenue disclosure because the company has no commercial sales

The company’s strategy is to advance IKT-001 through clinical development, secure regulatory approval, and preserve...

01
Complete and fund clinical development of IKT-001short-term

Clinical data are the main value driver for a company with no product revenue.

02
Strengthen biomarker and translational evidencemedium-term

Biomarker proof helps validate mechanism and support regulatory and partnering discussions.

03
Secure manufacturing and supply continuityshort-term

Dependence on China-based manufacturers can disrupt trials and delay commercialization.

04
Extend patent protection and exclusivitymedium-term

Longer exclusivity improves the commercial window if the product is approved.

The company faces classic biotech development risk: clinical failure, regulatory delay, and the possibility that safety...

critical

Clinical development failure

If IKT-001 does not demonstrate adequate efficacy or safety, the asset may not be approvable or commercializable.

Scope
PAH Phase 2b and future studies
Materiality
high
high

Financing risk

The company has recurring losses and needs substantial additional funding to continue development.

Scope
Public equity, private equity, debt, and other capital sources
Materiality
high
high

Regulatory approval risk

Approval is required before any product sales can begin, and regulators may request more data or reject the filing.

Scope
FDA and other health authorities
Materiality
high
high

China supply-chain concentration

Third-party manufacturers are located in China, so disruptions could delay clinical supply and increase costs.

Scope
Clinical and future commercial manufacturing
Materiality
high
medium

Geopolitical and trade restrictions

U.S.-China policy changes, tariffs, or data-related restrictions could impair sourcing and vendor relationships.

Scope
Cross-border manufacturing and vendor agreements
Materiality
medium
Research and development accruals
Can shift reported operating loss between periods
Milestone-based CRO obligations
May create future expense and liability recognition
Going-concern and liquidity disclosures
Affects investor assessment of runway and dilution risk
Contingent consideration and asset acquisition judgments
Could affect balance sheet and future earnings volatility

Inhibitor Therapeutics, Inc.

INTI · Pharmaceutical Preparations

Inhibrx Biosciences, Inc.

INBX · Biological Products, (No Diagnostic Substances)

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Neuraxis, INC

NRXS · Electromedical & Electrotherapeutic Apparatus

MANNKIND CORP

MNKD · Pharmaceutical Preparations

: 28.4.2026